Ejection fraction is back to normal-now what?
Chavey
William E
WE
Department of Family Medicine, University of Michigan, Ann Arbor, MI USA. wchavey@umich.edu
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015897:Comorbidity; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020127:Recovery of Function; D013318:Stroke Volume; D014463:Ultrasonography; D018754:Ventricular Dysfunction / Q000188:drug therapy*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists